Belatacept: Beyond the BENEFIT in Kidney Transplant Recipients

January 14, 2021

This activity will review current literature available evaluating the outcomes associated with early conversion post-kidney transplant (less than or equal to 6 months) as well as when utilized for late conversion (>1 year post-transplant). From this literature, the activity will de-lineate the potential risks and benefits seen when converting and attempt to answer the question of when to convert therapy. Additionally, this activity will review the literature regarding belatacept use in the high immunologic risk patient population to determine if use would be safe. Lastly, this activity will bring this information together to determine how best to apply it clinically to a patient’s immunosuppression regimen and what adjustments to the regimen are needed when initiating belatacept.

Target Audience

  • Pharmacists
  • Pharmacy technicians

Learning Objectives

Pharmacist learning objectives

  1. Identify toxicities associated with maintenance immunosuppression warranting conversion to belatacept therapy
  2. Summarize the unique mechanism of action association with belatacept
  3. Analyze available literature evaluating the use of belatacept conversion in kidney transplant recipients
  4. Design an alternative immunosuppression regimen utilizing belatacept therapy

Pharmacy technician learning objectives

  1. Identify common adverse effects of maintenance immunosuppressive medications
  2. Recognize the differences in dosage forms between belatacept and standard immunosuppressive therapy

Additional Information

AttachmentSize
PDF icon Helpful Tips for Users.pdf157.72 KB
File Information for CE Credit - Belatacept.docx125.29 KB
Course summary
Available credit: 
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Technician
  • 1.00 General CE – Attendance
Course opens: 
01/14/2021
Course expires: 
02/28/2021
Event starts: 
01/14/2021 - 12:00pm CST
Event ends: 
01/14/2021 - 1:00pm CST
Add to calendar: 
Ochsner Medical Center
New Orleans, LA
United States
Relevant financial relationships: Planning committee members and presenters have nothing to disclose
 
Planning committee members
Bailey Wise, PharmD, BCPS
Clinical Pharmacist
Ochsner Medical Center
 
Marissa Janusek, PharmD, BCPS
Abdominal Transplant Clinical Specialist
Ochsner Medical Center
 
Course reviewer
James Lichauer, PharmD, BCPS, FASHP
PI Program Director, Pharmacy
Vizient
 
Presenter
Bethany Lane, PharmD
PGY2 Solid Organ Transplant Resident
Ochsner Medical Center
 
Joint Accreditation Statement:
 
In support of improving patient care, this activity has been planned and implemented by Vizient, Inc. and Ochsner Medical Center.  Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
____________________________________________
 
Designation Statements:
 
PHARMACY
Vizient, Inc. designates this activity for a maximum of 1.00 ACPE credit hours.
Universal Activity Number: JA0006103-9999-21-073-L01-P
Universal Activity Number: JA0006103-9999-21-073-L01-T
 
CEU
Vizient, Inc. will award CEUs to each participant who successfully completes this program. The CEU is a nationally recognized unit of measure for continuing education and training programs that meet certain criteria (1 contact hour = 0.1 CEU).

Available Credit

  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Technician
  • 1.00 General CE – Attendance
Please login or register to take this course.